Skip to content
Biotechnology, Medical Health Aged Care

The Future of Skin Science: InMode and ExoCoBio introduce the most clinically validated exosome technology to New Zealand’s aesthetic market.

InMode Australia 2 mins read

This introduction brings one of the world’s most advanced exosome technologies to New Zealand, with two exclusive events set to take place in:

• Auckland – July 15, 2025 | The Boathouse, Park Hyatt Auckland, from 6:30pm

• Christchurch – July 17, 2025 | Chateau on the Park, DoubleTree by Hilton, from 6:30pm

 

These curated evenings will showcase the powerful synergy between ASCE+ Exosomes and InMode’s Morpheus8 technology, and feature:

• Live treatment demonstrations

• Keynote presentations from leading experts in regenerative science

• Clinical case studies and exclusive launch offers for attending practitioners

 

Key Speakers:

Dr Jean Paul Chung, Aesthetic Physician & Educator (Sydney), will present clinical insights and protocols using ASCE+ in skin rejuvenation.

Mr Byong Seung Cho, CEO & CTO of ExoCoBio, South Korea, will offer a rare insider’s perspective into the research and development behind ASCE+, and its role in reshaping global skin health.

 

Powered by ExoSCRT™, ExoCoBio’s proprietary purification technology, ASCE+ Exosomes are designed to optimise cell-to-cell communication, stimulate repair, and visibly revitalise the skin. Backed by science and trusted globally, ASCE+ is now set to raise the standard for non-invasive skin regeneration in the New Zealand market.

 

Adding to this innovation is the InMode Optimas Max, a powerful multi-platform workstation designed to deliver advanced skin treatments across various modalities -including radiofrequency, IPL, and laser technologies. With applicators such as Morpheus8 Burst, Lumecca Peak, and Forma, Optimas Max offers unparalleled versatility for skin resurfacing, tightening, and pigmentation correction - all in one streamlined device. It enables clinics to offer results-driven treatments with minimal downtime and maximum efficacy.

 

When paired with ASCE+ Exosomes, the Optimas Max system becomes a next-generation aesthetic powerhouse. The synergy between energy-based modalities and regenerative exosome therapy enhances treatment outcomes dramatically - accelerating recovery, improving skin texture, and promoting lasting rejuvenation. This combination delivers a compelling value proposition for clinics and practitioners committed to offering cutting-edge, science-backed solutions for their patients.

 

RSVP – https://event.inmodeau.com/asce_exosomes_nz


About us:

About InMode Australia

InMode is a market leader in energy-based medical technologies, providing cutting-edge, clinically validated solutions across Australia and New Zealand.

 

About ExoCoBio

ExoCoBio is a globally recognised innovator in exosome therapeutics and regenerative aesthetics, dedicated to delivering science-driven skincare solutions through advanced biologics.


Contact details:

Media Contact:
Patricia Amalm
Mobile: 0499 197 069
Email:
[email protected]
Website:
www.inmode.com.au

Follow Us on Instagram

Media

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.